Almost 2 tons of ground beef recalled over E. coli in 9 states
Elkhorn Valley Packing is recalling 1.7 tons of ground beef after a sample from the Kansas-based meat packer tested positive for E. coli, the U.S. Department of Agriculture (USDA) announced on Friday. The notice said that more than 3,400 pounds of the boneless beef chuck was packaged on Feb. 16…#valleypacking #kansas #usda #steco103 (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2023 Category: Consumer Health News Source Type: news
3.4K Pounds Of Beef Chuck Product Recalled Due To Possible E. Coli Contamination
Thousands of pounds of a beef chuck product are being recalled due to possible E. coli contamination. Approximately 3,436 pounds of various weights of boneless items labeled "Elkhorn Valley Pride Angus Beef 61226 BEEF CHUCK 2PC BNLS" were packed on Thursday, Feb. 16, the US Department of…#fsis #usda #connecticut #massachusetts #newjersey #pennsylvania #illinois #indiana #maryland #michigan (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2023 Category: Consumer Health News Source Type: news
E. Coli From Meat May Be Causing Many UTIs
FRIDAY, March 24, 2023 -- E. coli bacteria are an infamous cause of food poisoning, but a new study suggests those same microbes lurking in meat may be behind nearly half a million cases of urinary tract infections (UTIs).
UTIs are very common,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 24, 2023 Category: General Medicine Source Type: news
Undercooked meat may be to blame for one in 14 UTIs, scientists say
US scientists have now found between 480,000 and 640,000 UTIs could be triggered by E Coli found in raw meat. This bacteria can live in the gut before ending up in the urinary tract. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2023 Category: Consumer Health News Source Type: news
Blood Thinner Recall; Marburg Cases Triple; E. Coli in Meat May Cause 500,000 UTIs
(MedPage Today) -- Note that some links may require subscriptions.
At FDA's request, Ascend Laboratories has voluntarily recalled certain lots of the blood thinner dabigatran because of possible contamination with a nitrosamine.
Eighty-hour work... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 24, 2023 Category: Cardiology Source Type: news
Mayo Clinic Minute: Avoiding summer E. coli infection
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - March 24, 2023 Category: Consumer Health News Source Type: news
E coli from meat behind half a million UTIs in the US every year, study suggests
Fatal bloodstream illnesses driven by urinary tract infections could rise, warn scientists as research shows link to food-borne bacteriaMeat bacteria are the likely cause of over half a million urinary tract infections (UTIs) in the US every year, a new study has found, with one of its authors warning that deaths from UTI-driven bloodstream infections could be on the rise.The study found that of the 6-8m UTIs caused by E coli bacteria in the US every year, between 480,000 and 640,000 could be linked to strains known as FZECs, or food-borne zoonotic E coli. Women are far more likely than men tosuffer from UTIs. The British ...
Source: Guardian Unlimited Science - March 23, 2023 Category: Science Authors: Sophie Kevany Tags: E coli Meat Health Food Meat industry Environment Society Medical research Antibiotics Science Food safety World news Farm animals US news UK news Source Type: news
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Shigellosis: The rise of an antibiotic-resistant stomach bug
The Centers for Disease Control and Prevention issued a health alert in February saying it was monitoring a rise in drug-resistant Shigella infections, leaving doctors concerned over what this could mean for other bacteria. Here's everything you need to know: What is Shigella? Shigella is a…#shigella #cdc #stephenbaker #times #ecoli (Source: Reuters: Health)
Source: Reuters: Health - March 16, 2023 Category: Consumer Health News Source Type: news
How to tell the difference between shigella and norovirus as stomach flus rise
Cases of norovirus - or the 'stomach flu ' - reached a 12-month high in February and are still wreaking havoc, particularly in US schools. At the same time, cases of Shigella infections are on the rise. (Source: the Mail online | Health)
Source: the Mail online | Health - March 15, 2023 Category: Consumer Health News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
A ‘super strain’ of an antibiotic-resistant stomach bug is on the rise in the U.S. Here are the symptoms to watch for
Antibiotic resistance is once again making headlines—this time not involving an STD, but a brutal GI illness that can also spread sexually. In January, U.S. public health officials warned of a so-called “super strain” of gonorrhea resistant to many types of antibiotics usually used to treat it. A…#std #casesofxdr #shigella #cdc #colorado #xdrshigella #racheljervis #xdr #jervis #eating (Source: Reuters: Health)
Source: Reuters: Health - March 4, 2023 Category: Consumer Health News Source Type: news
What to know about Shigella, the drug-resistant stomach bug on the rise
A recent health advisory described these infections as a “serious public health threat.” (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - March 3, 2023 Category: Consumer Health News Authors: Lena H. Sun Source Type: news
What is Shigella, the increasingly drug-resistant bacteria the CDC is warning about?
Shigella causes shigellosis, an inflammatory diarrhea. The extensively drug-resistant strain is relatively uncommon overall, but it's being seen in more cases among adults. (Image credit: Stephanie Rossow/Science Source) (Source: NPR Health and Science)
Source: NPR Health and Science - March 3, 2023 Category: Consumer Health News Authors: Kaitlyn Radde Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
